Clinical trials: PEG-rhG-CSF
Lymphoma, Leukemia
Evaluate the Efficacy and Safety of the Prophylactic Use of PEG-rhG-CSF in Children With Hematological Malignancies
The incidence of infectious complications in hematological malignancies is higher than that in children with solid tumors, which may be related to the type and dose intensity of chemotherapy regimens used in hematological tumors.
- Trial name
- NCT04497701
- Testing
- PEG-rhG-CSF group, rhG-CSF group
- Where
- China
- Volunteers
- 139 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Myelosuppression, Thoracic Neoplasms
Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy
This is a prospective observational study designed to observe and evaluate the safety and efficacy of mecapegfilgrastim in the treatment of moderate-to-severe myelosuppression associated with concurrent chemoradiotherapy.
- Conditions
- Myelosuppression, Thoracic Neoplasms, Chemoradiotherapy
- Trial name
- ANC-IIT-004 (NCT07205536)
- Testing
- Mecapegfilgrastim injection, Oral or short-acting granulocyte-stimulating agents
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Affiliated Hospital of Nantong University
Lymphoma
PEG-rhG-CSF Compared With rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation
The purpose of the study is to evaluate the efficacy and safety of PEG-rhG-CSF compared with rhG-CSF on the recovery of hematopoietic function after autologous stem cell transplantation in patients with lymphoma.
- Trial name
- NCT05156554
- Testing
- PEG-rhG-CSF, rhG-CSF
- Volunteers
- 80 people
- Sponsor
- Sun Yat-sen University
Adjuvant Chemotherapy, Ovarian Neoplasms
Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer
This study is a multicenter, open-label, randomized clinical trial. Patients with ovarian cancer receiving postoperative adjuvant chemotherapy were eligible to enroll in this study.
- Conditions
- Adjuvant Chemotherapy, Ovarian Neoplasms, Ovarian Cancer
- Trial name
- NCT03858166
- Testing
- PEG-rhG-CSF
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Shandong University
Lymphoma
PEG-rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation
The purpose of the study is to evaluate the efficacy and safety of PEG-rhG-CSF on the recovery of hematopoietic function after autologous stem cell transplantation in patients with lymphoma.
- Trial name
- NCT02905942
- Testing
- PEG-rhG-CSF, rhG-CSF
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Peking University
Non Hodgkin's Lymphoma
Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's Lymphoma
The main treatments for non-Hodgkin's lymphoma are surgery, radiotherapy, chemotherapy, and bone marrow transplantation. Neutropenia is the most common and serious complication of most chemotherapy.
- Trial name
- NCT04497688
- Testing
- PEG-rhG-CSF
- Where
- China
- Volunteers
- 104 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Breast Cancer Female
Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF
In the study, subjects will scheduled to undergo four 21-days cycles of chemotherapy treatment. Three group were treated with MW05 300 μg/kg or MW05 500 μg/kg or PEG-rhG-CSF 100 μg/kg on the 3th day of each cycle randomized 1:1:1…
- Trial name
- NCT04554056
- Testing
- MW05, PEG-rhG-CSF
- Where
- China
- Volunteers
- 586 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Lymphoma
Clinical Study on PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells
This study is a randomized controlled, open and multi-center clinical study. Patients who meet the selection criteria and do not meet the exclusion criteria are randomly given PEG-rhG-CSF with a fixed dose of 12mg when white…
- Trial name
- NCT06026995
- Testing
- PEG-rhG-CSF, RhG-CSF
- Where
- China
- Volunteers
- 174 people
- Sponsor
- Chongqing University Cancer Hospital
Cervical Cancer
To Evaluate the Efficacy and Safety of PEG-rhG-CSF（Jinyouli®） in Reducing Neutropenia in Patients With Cervical Cancer
A Prospective, open, randomized, controlled clinical study to evaluate the efficacy and safety of PEG-rhG-CSF(PEGylated recombinant human granulocyte stimulating factor injection) in reducing neutropenia during…
- Trial name
- NCT03206684
- Testing
- PEG-rhG-CSF, rhG-CSF
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Air Force Military Medical University, China
Breast Cancer
PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy to Prevent Neutropenia
The purpose of this study is to estimate the efficacy and safety of PEG-rhG-CSF in patients with breast cancer receiving chemotherapy.
- Trial name
- NCT02805205
- Testing
- PEG-rhG-CSF
- Volunteers
- 484 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Febrile Neutropenia
Prophylactic Use of PEG-rhG-CSF in Medium-high Risk of FN in Chemotherapy of Breast Cancer
This clinical study is a multiple center, registering and real-world conditional research. The breast cancer patients planning for chemotherapy evaluated with medium-high risk of febrile neutropenia (FN) are recruited, receiving…
- Trial name
- NCT03618810
- Testing
- PEGCSF first level prophylactic use, PEGCSF second level prophylactic use
- Volunteers
- 2,000 people
- Sponsor
- Zhejiang Cancer Hospital
Neutropenia
A Real World Study Evaluating the Clinical Application of PEG-rhG-CSF During Chemotherapy in Patients With Solid Tumors
Prospective, multicenter, non-interventional registration studies were used in this project . Eight hundreds patients with solid tumors who met the inclusion criteria in six hospitals in Sichuan Province, Sichuan Province, were…
- Trial name
- NCT03798665
- Testing
- Pegfilgrastim（PEG-rhG-CSF）
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Affiliated Hospital of North Sichuan Medical College
Acute Lymphoid Leukemia
The Study on the Pharmacokinetics of PEG-rhG-CSF in Children and Adolescents
The purpose of the trail is to study the pharmacokinetics of Pegylated Recombinant Human Granulocyte Stimulating Factor（PEG-rhG-CSF） in Children and Adolescents
- Trial name
- NCT02953730
- Testing
- PEG-rhG-CSF
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Chinese Academy of Medical Sciences
Chemotherapy-induced Neutropenia
Efficacy, Safety and Cost-effectiveness of PEG-rhG-CSF for Primary vs Secondary Prophylaxis
This trial is a multicenter, non-interventional, registered real-world clinical study. Based on available evidence and recommendations of guidelines, tumor patients with high risk of FN and eligible for all enrollment criteria…
- Trial name
- NCT03701841
- Testing
- PEG-rhG-CSF
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Anhui Provincial Hospital
Small Cell Lung Cancer
Mecapegfilgrastim Prevents Neutropenia and Radiation Esophagitis
Evaluation of the efficacy and safety of Mecapegfilgrastim for the prevention of neutropenia and radiation esophagitis after hyperfractionation in patients with limited-stage small cell lung cancer
- Trial name
- NCT04171986
- Testing
- Mecapegfilgrastim
- Where
- China
- Volunteers
- 93 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Metastatic Breast Cancer
Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer
Neutropenia is a common complication from dalpiciclib. Mecapegfilgramtim (code name HHPG-19K), a long-acting recombinant human granulocyte colony-stimulating factor (rhG-CSF), has been developed.
- Trial name
- NCT05463601
- Testing
- Mecapegfilgrastim, dalpiciclib, exemestane, fulvestrant, letrozole, tamoxifen
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Small Cell Lung Cancer, PEG-rhG-CSF
PEG-rhG-CSF in Elderly Patients With Small Cell Lung Cancer Receiving Chemotherapy
Evaluation of the efficacy and safety of Jinyouli in preventing neutropenia in multiple chemotherapy cycles in elderly patients with small cell lung cancer through a multicenter, open, one-arm study Subjects with newly diagnosed…
- Trial name
- NCT03776604
- Testing
- PEG-rhG-CSF
- Where
- China
- Volunteers
- 61 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Pediatric Cancer
Safety and Efficacy of PEG-rhG-CSF in Preventing Neutropenia in Children With Tumor After Chemotherapy
The purpose is to evaluate the safety of PEG-rhG-CSF in the prevention of neutropenia in children with tumor after chemotherapy, and then evaluate the effectiveness of PEG-rhG-CSF in preventing neutropenia in children with tumor…
- Trial name
- NCT04547829
- Testing
- pegylated recombinant human granulocyte-colony stimulating factor
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Sun Yat-sen University
Chemotherapy-induced Neutropenia, Myelosuppression
Real World Study of PEG-rhG-CSF in Prevention of Chemotherapy-induced Neutropenia
The aim of this study is to observe and evaluate the cost-effectiveness,efficacy and safety of PEG-rhG-CSF in preventing chemotherapy-induced neutropenia(CIN) of cancer patients in the real world.1000 patients with non-myeloid…
- Trial name
- NCT03846414
- Testing
- PEG-rhG-CSF
- Volunteers
- 1,500 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Multiple Myeloma, Lymphoma
Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
This is a multicenter prospective study to evaluate the efficacy and safety of chemotherapy combined with a single dose of subcutaneous(SC) injection mecapegfilgrastim on day 2 or day 5 after chemotherapy for autologous…
- Trial name
- NCT05294055
- Testing
- Etoposide, Cyclophosphamide, Mecapegfilgrastim, day 2
- Where
- 7 sites in China
- Volunteers
- 120 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China